Foresite Capital

United States
Foresite Capital is a multi-stage healthcare and life sciences investment firm that applies rigorous scientific and data-driven approaches to investment analysis. The firm has $2 billion under management. Foresite Capital takes a collaborative approach to investing with its portfolio companies by providing a multidisciplinary team of scientists,engineers, analysts, and clinicians who understand the unique business models in healthcare in addition to capital. The company aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles. Its portfolio also emphasizes companies that are employing the tools of data science and machine intelligence in healthcare. Foresite Capital is based in San Francisco with an office in New York.
Founded:2011
Firm Location:United States • California • Pennsylvania • Nevada • New Jersey • Delaware • New York, New York • Los Angeles, California • Philadelphia, Pennsylvania • San Francisco, California • Denver, Colorado • Boston, Massachusetts • Worcester, Massachusetts • New Haven, Connecticut
Foresite Capital Team
Photo of Deepak Atri, Analyst at Foresite Capital
Deepak Atri
Sweet spot: $38.5M
Range: $2.0M - $75.0M
Investors in United States
Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Medical Devices (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in BioTech (Seed), Investors in Drug Delivery (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Health IT (Series B), Investors in Health IT (Seed)
Photo of Luke Bagaason, Analyst at Foresite Capital
Luke Bagaason
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Denver (CO)
Photo of Vikram Bajaj, Managing Director at Foresite Capital
Vikram Bajaj
Foresite Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA), Investors in Nevada
Photo of Jacob Barlow, Senior Associate at Foresite Capital
Jacob Barlow
Foresite Capital·Senior Associate
Sweet spot: $10.0M
Range: $1M - $25.0M
Investors in Cambridge (MA)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series A), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Medical Devices (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in BioTech (Seed), Investors in Drug Delivery (Series A), Investors in Therapeutics (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B)
Photo of Shannon Bergstedt, Principal at Foresite Capital
Shannon Bergstedt
Foresite Capital·Principal
Sweet spot: $38.5M
Range: $2.0M - $75.0M
Investors in New York (NY)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Medical Devices (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series A), Investors in New York City (Other Lists), Investors in BioTech (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Health IT (Series B), Investors in Health IT (Seed)
Photo of Hyung Chun, Partner at Foresite Capital
Hyung Chun
Sweet spot: $38.5M
Range: $2.0M - $75.0M
Investors in New Haven (CT)
Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in BioTech (Seed)
Photo of Marguerite Davis, Foresite Capital
Marguerite Davis
Sweet spot: $38.5M
Range: $2.0M - $75.0M
Investors in SF Bay Area (CA)
Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in Diagnostics (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Seed), Investors in Therapeutics (Series A), Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Drug Delivery (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Drug Delivery (Seed), Investors in Digital Health (Seed), Investors in Drug Delivery (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series B), Investors in Drug Delivery (Series A), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in BioTech (Seed), Investors in San Francisco Bay Area (Other Lists)
Photo of Shoman Kasbekar, Principal at Foresite Capital
Shoman Kasbekar
Foresite Capital·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Photo of Richard Lau, Partner at Foresite Capital
Richard Lau
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Photo of Dorothy Margolskee, Managing Partner at Foresite Capital
Dorothy Margolskee
Foresite Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New Jersey
Photo of Stephen Peterson, Managing Director at Foresite Capital
Stephen Peterson
Foresite Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Denver (CO)
Photo of Hemaka Rajapakse, Managing Director at Foresite Capital
Hemaka Rajapakse
Foresite Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Pennsylvania
Photo of Jonathan Robbins, Investor at Foresite Capital
Jonathan Robbins
Sweet spot: $38.5M
Range: $2.0M - $75.0M
Investors in Boston (MA), Investors in Boston / New England
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series A), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Medical Devices (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Digital Health (Seed), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series B), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Drug Delivery (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Drug Delivery (Series A), Investors in Digital Health (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Health IT (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Health IT (Series B)
Photo of Michael Rome, Managing Director at Foresite Capital
Michael Rome
Foresite Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Los Angeles (CA)
Photo of Dennis Ryan, Managing Director at Foresite Capital
Dennis Ryan
Foresite Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in California
Photo of Jim Tananbaum, Investor at Foresite Capital
Jim Tananbaum
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Photo of Tony Wiemelt, Managing Director at Foresite Capital
Tony Wiemelt
Foresite Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Photo of Cindy Xiong, Investor at Foresite Capital
Cindy Xiong
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York City
Photo of Collin Yang-Wong, Analyst at Foresite Capital
Collin Yang-Wong
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)